In the present study, SRPK1 was found to be highly expressed in gefitinib-resistant cells, and high SRPK1 expression was independently associated with poor prognosis in 65 NSCLC patients who underwent EGFR-TKI therapy, indicating that SRPK1 plays an important role in EGFR-TKI resistance. This evidence concerns the gene EGFR and non-small cell lung carcinoma.